A total of over 30 million confirmed COVID-19 cases have been reported across the globe, with the number of deaths nearing one million as of mid-September. With these grim numbers continuing to increase, new treatment approaches are being explored to tackle the pandemic. This is the case of U.S-based Atossa Therapeutics Inc., which is currently conducting a clinical trial for developing ‘AT-301’ nasal sprays in a bid to develop a new treatment option for early-stage COVID-19.
The biopharmaceutical company reportedly announced positive safety outcomes from the second group of healthy individuals in Phase 1 clinical trial using the company’s proprietary drug named ‘AT-301’ administered by nasal spray. The eight participants received a single dose of either AT-301B (active drug) or AT-301A (placebo). The blinded, positive evaluation by the safety committee allows the trial to enroll in the next cohort.
Speaking on which, Steven Quay who is the CEO and President of Atossa said that the positive outcomes from the safety trial marked a pivotal milestone in this clinical trial as half the individual has now been dosed and primary safety reviews have been completed. He added that the company is developing an AT-301 nasal spray for in-house use as there are no presently FDA-approved treatments to help early state COVID-19 patients.
In recent months, considerable advancements have been made in the field of diagnostic testing of COVID-19. These testing methods are now easily available and they can demonstrate results in less time. Atossa is planning to partner with COVID-19 diagnostic companies to ensure the availability of AT-301 spray treatment at the time a person tests positive for the coronavirus.
Sources cite that the company is also planning to develop its nasal spray to help safeguard COVID-19 infection, especially for people working in high-risk areas, including emergency responders, healthcare workers, and teachers.
Source Credit - https://www.globenewswire.com/news-release/2020/09/17/2095284/0/en/Atossa-Therapeutics-Receives-Second-Positive-Interim-Safety-Assessment-in-Clinical-Study-of-AT-301-Nasal-Spray-Being-Developed-for-the-Coronavirus-Causing-COVID.html